The stock of Rani Therapeutics Holdings Inc (NASDAQ:RANI) last traded at $0.51, down -1.15% from the previous session.
RANI stock price is now -37.69% away from the 50-day moving average and -68.41% away from the 200-day moving average. The market capitalization of the company currently stands at $29.23M.
With the price target of $17, Oppenheimer recently initiated with Outperform rating for Rani Therapeutics Holdings Inc (NASDAQ: RANI). On June 14, 2024, Maxim Group recently initiated its ‘Buy’ rating on the stock quoting a target price of $15, while ‘Rodman & Renshaw’ rates the stock as ‘Buy’
In other news, McKinley Kate, Chief Business Officer bought 17,960 shares of the company’s stock on Dec 13 ’24. The stock was bought for $29,993 at an average price of $1.67. Upon completion of the transaction, the Chief Business Officer now directly owns 17,960 shares in the company, valued at $9159.6. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 09 ’24, Chief Executive Officer Imran Talat bought 10,296 shares of the business’s stock. A total of $19,974 was incurred on buying the stock at an average price of $1.94. This leaves the insider owning 494,751 shares of the company worth $0.25 million. A total of 32.12% of the company’s stock is owned by insiders.
During the past 12 months, Rani Therapeutics Holdings Inc has had a low of $0.46 and a high of $4.37.
The net profit margin was -2483.25% and return on equity was -1372.59% for RANI.
